Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Fibrosis Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SFRP2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SFRP2 Recombinant Protein (ECD-Fc / His-tag) High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. HEK293 expressed for native glycosylation. |
View SFRP2 Products |
| Gene Delivery | SFRP2 Promise-ORF / Lentivirus Full-length ORF for stable cell line development and overexpression assays. |
View SFRP2 Products |
| Benchmark Ab | Anti-SFRP2 Recombinant Antibody Recombinant positive control derived from clinical/preclinical benchmark clones. |
View SFRP2 Products |
| Validator | SFRP2 siRNA Set Target-specific siRNA pool for target knockdown and specificity validation. |
View SFRP2 Products |
| Related Target A | WNT3A Primary canonical Wnt ligand; critical for establishing competitive binding and functional rescue assays. |
View WNT3A Products |
| Related Target B | FZD7 Frizzled-7 receptor; key partner for validating SFRP2 cysteine-rich domain (CRD) interactions. |
View FZD7 Products |
| Related Target C | SFRP1 Subfamily homolog; essential for counter-screening to ensure antibody selectivity and avoid off-target toxicity. |
View SFRP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| CRD Homology Cross-Reactivity | SFRP1, SFRP2, and SFRP5 homolog panel proteins strictly verified by mass spectrometry and sequence analysis to ensure epitope differentiation. |
| Post-Translational Glycosylation Integrity | HEK293 mammalian expression host ensures native folding and correct glycosylation patterns, matching endogenous human SFRP2. |
| Lack of Reliable Controls | Clinical-grade benchmark biosimilar antibodies included for assay standardization. |
| Non-specific Binding in SPR/BLI | Carrier-free, high-purity (>95%) formulations with controlled endotoxin levels (<1.0 EU/μg) to minimize background noise in biophysical assays. |
Live SFRP2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Secreted Frizzled-Related Protein 2 (SFRP2) is emerging as a highly promising strategy at the intersection of oncology, angiostatic therapy, and tissue fibrosis. SFRP2 acts as a biphasic modulator of Wnt signaling. In the tumor microenvironment, particularly in triple-negative breast cancer (TNBC), angiosarcoma, and osteosarcoma, SFRP2 overexpression promotes pathological angiogenesis and tumor progression. Conversely, in cardiac and renal tissue remodeling, SFRP2 is deeply involved in pro-fibrotic signaling pathways.
The race for SFRP2 therapeutics is intensifying, with major players shifting focus from traditional systemic Wnt inhibitors to localized or highly selective monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). As first-generation therapies reach preclinical and early clinical milestones, the next wave of R&D is targeting highly specific epitopes within the SFRP2 Cysteine-Rich Domain (CRD) to block Wnt/Frizzled interaction without triggering systemic bone or metabolic toxicity associated with pan-SFRP inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Academic Institutes, Biotech Startups | Solid Tumors, Angiosarcoma, TNBC | Wnt-pathway blocking assays (Requires high-purity SFRP2 ECD protein to compete with Wnt ligands) |
| Anti-Fibrotic Therapeutics | Cardiovascular Research Consortiums | Myocardial Infarction, Renal Fibrosis | In vitro cell-based assays (Requires sequence-verified SFRP2 lentivirus for stable cell line generation) |
| Bispecific / Multi-specific | Oncology-focused Biopharma | Metastatic Osteosarcoma | Selectivity assays (Requires SFRP subfamily homolog proteins like SFRP1 to rule out off-target binding) |